S&P 500   5,253.21 (+0.09%)
DOW   39,764.17 (+0.01%)
QQQ   444.19 (-0.14%)
AAPL   171.13 (-1.26%)
MSFT   420.21 (-0.29%)
META   488.37 (-1.11%)
GOOGL   151.27 (+0.27%)
AMZN   180.06 (+0.13%)
TSLA   177.03 (-1.56%)
NVDA   904.68 (+0.24%)
NIO   4.66 (-0.21%)
AMD   180.99 (+0.78%)
BABA   72.19 (+0.84%)
T   17.69 (+0.80%)
F   13.23 (+1.30%)
MU   119.23 (+0.08%)
CGC   9.03 (-5.45%)
GE   176.13 (-2.22%)
DIS   122.15 (+0.97%)
AMC   3.84 (-11.52%)
PFE   27.86 (+0.29%)
PYPL   66.83 (+0.39%)
XOM   115.59 (+0.54%)
S&P 500   5,253.21 (+0.09%)
DOW   39,764.17 (+0.01%)
QQQ   444.19 (-0.14%)
AAPL   171.13 (-1.26%)
MSFT   420.21 (-0.29%)
META   488.37 (-1.11%)
GOOGL   151.27 (+0.27%)
AMZN   180.06 (+0.13%)
TSLA   177.03 (-1.56%)
NVDA   904.68 (+0.24%)
NIO   4.66 (-0.21%)
AMD   180.99 (+0.78%)
BABA   72.19 (+0.84%)
T   17.69 (+0.80%)
F   13.23 (+1.30%)
MU   119.23 (+0.08%)
CGC   9.03 (-5.45%)
GE   176.13 (-2.22%)
DIS   122.15 (+0.97%)
AMC   3.84 (-11.52%)
PFE   27.86 (+0.29%)
PYPL   66.83 (+0.39%)
XOM   115.59 (+0.54%)
S&P 500   5,253.21 (+0.09%)
DOW   39,764.17 (+0.01%)
QQQ   444.19 (-0.14%)
AAPL   171.13 (-1.26%)
MSFT   420.21 (-0.29%)
META   488.37 (-1.11%)
GOOGL   151.27 (+0.27%)
AMZN   180.06 (+0.13%)
TSLA   177.03 (-1.56%)
NVDA   904.68 (+0.24%)
NIO   4.66 (-0.21%)
AMD   180.99 (+0.78%)
BABA   72.19 (+0.84%)
T   17.69 (+0.80%)
F   13.23 (+1.30%)
MU   119.23 (+0.08%)
CGC   9.03 (-5.45%)
GE   176.13 (-2.22%)
DIS   122.15 (+0.97%)
AMC   3.84 (-11.52%)
PFE   27.86 (+0.29%)
PYPL   66.83 (+0.39%)
XOM   115.59 (+0.54%)
S&P 500   5,253.21 (+0.09%)
DOW   39,764.17 (+0.01%)
QQQ   444.19 (-0.14%)
AAPL   171.13 (-1.26%)
MSFT   420.21 (-0.29%)
META   488.37 (-1.11%)
GOOGL   151.27 (+0.27%)
AMZN   180.06 (+0.13%)
TSLA   177.03 (-1.56%)
NVDA   904.68 (+0.24%)
NIO   4.66 (-0.21%)
AMD   180.99 (+0.78%)
BABA   72.19 (+0.84%)
T   17.69 (+0.80%)
F   13.23 (+1.30%)
MU   119.23 (+0.08%)
CGC   9.03 (-5.45%)
GE   176.13 (-2.22%)
DIS   122.15 (+0.97%)
AMC   3.84 (-11.52%)
PFE   27.86 (+0.29%)
PYPL   66.83 (+0.39%)
XOM   115.59 (+0.54%)
NASDAQ:AMRN

Amarin (AMRN) Stock Price, News & Analysis

$0.90
+0.01 (+0.82%)
(As of 09:47 AM ET)
Today's Range
$0.88
$0.90
50-Day Range
$0.82
$1.35
52-Week Range
$0.65
$1.56
Volume
30,926 shs
Average Volume
2.17 million shs
Market Capitalization
$368.17 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$1.08

Amarin MarketRank™ Stock Analysis

Analyst Rating
Reduce
1.75 Rating Score
Upside/​Downside
21.8% Upside
$1.08 Price Target
Short Interest
Bearish
4.43% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.81mentions of Amarin in the last 14 days
Based on 8 Articles This Week
Insider Trading
Acquiring Shares
$15,724 Bought Last Quarter
Proj. Earnings Growth
Decreasing
From ($0.14) to ($0.20) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

0.78 out of 5 stars

Medical Sector

845th out of 939 stocks

Pharmaceutical Preparations Industry

386th out of 430 stocks

AMRN stock logo

About Amarin Stock (NASDAQ:AMRN)

Amarin Corporation plc, a pharmaceutical company, engages in the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States, European countries, Canada, Lebanon, and the United Arab Emirates. It offers VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia. The company sells its products principally to wholesalers and specialty pharmacy providers. It has a collaboration with Mochida Pharmaceutical Co., Ltd. to develop and commercialize drug products and indications based on the active pharmaceutical ingredient in Vascepa. The company was formerly known as Ethical Holdings plc and changed its name to Amarin Corporation plc in 1999. Amarin Corporation plc was incorporated in 1989 and is headquartered in Dublin, Ireland.

AMRN Stock Price History

AMRN Stock News Headlines

my top trade on these 9 tickers
This indicator is uniquely designed to spot the most significant moves in the top stocks out there (and according to our backtesting it has historically nailed these moves with a stunning 90% accuracy). Now, most folks have been saying NVDA is way overbought or overpriced. They didn’t want to “buy at the top” 6 weeks ago… Or again 4 weeks ago… or again 2 weeks ago… And it’s not their fault! That’s what all the talking heads were saying too. But the Apex Indicator would have clearly shown that these were opportunities to buy. And, sure enough, Nvidia slammed through the recommended targets again and again.
AMRN Apr 2024 3.000 call
AMRN Apr 2024 1.500 put
AMRN May 2024 1.000 call
AMRN Mar 2024 0.500 call
$25,000 into $109,616 in two months?
Today I want to show you how our research shows you could’ve grown a $25,000 account into $109,616.12 within the last TWO months. You see, former multi-million dollar hedge fund manager Roger Scott spent the better half of 2023 developing what might be the most advanced trading tool that exists… It’s a revolutionary software system that tracks the moves of institutional investors…. in real time…
Amarin Full Year 2023 Earnings: Beats Expectations
Amarin Q4 2023 Earnings Preview
Amarin Chairman & CEO Issue Letter to Shareholders
Are Medical Stocks Lagging Amarin (AMRN) This Year?
Are Medical Stocks Lagging Amarin (AMRN) This Year?
See More Headlines
Receive AMRN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Amarin and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/29/2024
Today
3/27/2024
Next Earnings (Estimated)
5/01/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:AMRN
Fax
N/A
Employees
275
Year Founded
1991

Price Target and Rating

Average Stock Price Target
$1.08
High Stock Price Target
$1.25
Low Stock Price Target
$1.00
Potential Upside/Downside
+21.8%
Consensus Rating
Reduce
Rating Score (0-4)
1.75
Research Coverage
4 Analysts

Profitability

Net Income
$-59,110,000.00
Pretax Margin
-17.49%

Debt

Sales & Book Value

Annual Sales
$306.91 million
Book Value
$1.35 per share

Miscellaneous

Free Float
402,623,000
Market Cap
$365.17 million
Optionable
Optionable
Beta
2.01

Social Links

A Guide To High-Short-Interest Stocks Cover

MarketBeat's analysts have just released their top five short plays for April 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.

Get This Free Report

AMRN Stock Analysis - Frequently Asked Questions

Should I buy or sell Amarin stock right now?

4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Amarin in the last year. There are currently 2 sell ratings, 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "reduce" AMRN shares.
View AMRN analyst ratings
or view top-rated stocks.

What is Amarin's stock price target for 2024?

4 equities research analysts have issued 12-month price targets for Amarin's stock. Their AMRN share price targets range from $1.00 to $1.25. On average, they predict the company's share price to reach $1.08 in the next year. This suggests a possible upside of 21.8% from the stock's current price.
View analysts price targets for AMRN
or view top-rated stocks among Wall Street analysts.

How have AMRN shares performed in 2024?

Amarin's stock was trading at $0.87 at the start of the year. Since then, AMRN stock has increased by 2.2% and is now trading at $0.8892.
View the best growth stocks for 2024 here
.

Are investors shorting Amarin?

Amarin saw a increase in short interest during the month of March. As of March 15th, there was short interest totaling 18,190,000 shares, an increase of 7.1% from the February 29th total of 16,990,000 shares. Based on an average trading volume of 2,310,000 shares, the short-interest ratio is currently 7.9 days.
View Amarin's Short Interest
.

When is Amarin's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 1st 2024.
View our AMRN earnings forecast
.

How were Amarin's earnings last quarter?

Amarin Co. plc (NASDAQ:AMRN) announced its earnings results on Thursday, February, 29th. The biopharmaceutical company reported ($0.01) earnings per share for the quarter, topping the consensus estimate of ($0.05) by $0.04. The biopharmaceutical company had revenue of $74.71 million for the quarter, compared to the consensus estimate of $72.46 million. Amarin had a negative trailing twelve-month return on equity of 10.47% and a negative net margin of 19.26%.

What guidance has Amarin issued on next quarter's earnings?

Amarin updated its fourth quarter 2023 earnings guidance on Wednesday, January, 10th. The company provided EPS guidance of for the period. The company issued revenue guidance of $72.0 million-$74.0 million, compared to the consensus revenue estimate of $62.0 million.

What is John Thero's approval rating as Amarin's CEO?

43 employees have rated Amarin Chief Executive Officer John Thero on Glassdoor.com. John Thero has an approval rating of 93% among the company's employees. This puts John Thero in the top 30% of approval ratings compared to other CEOs of publicly-traded companies. 49.0% of employees surveyed would recommend working at Amarin to a friend.

What other stocks do shareholders of Amarin own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Amarin investors own include Micron Technology (MU), Advanced Micro Devices (AMD), NVIDIA (NVDA), Block (SQ), Alibaba Group (BABA), Tesla (TSLA), Bank of America (BAC), Netflix (NFLX) and Novavax (NVAX).

Who are Amarin's major shareholders?

Amarin's stock is owned by a number of retail and institutional investors. Top institutional investors include DG Capital Management LLC (1.34%), SCP Investment LP (0.62%), Hayek Kallen Investment Management (0.25%), Axxcess Wealth Management LLC (0.24%), 13D Management LLC (0.23%) and GSA Capital Partners LLP (0.21%). Insiders that own company stock include David M Stack, Joseph S Zakrzewski, Michael Wayne Kalb, Olsen Per Wold, Patrick Holt and Steven B Ketchum.
View institutional ownership trends
.

How do I buy shares of Amarin?

Shares of AMRN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Does Amarin have any subsidiaries?
The following companies are subsidiares of Amarin: Amarin France SAS, Amarin Germany GmbH, Amarin Italy S.r.l, Amarin Pharma Inc., Amarin Pharmaceuticals Ireland Limited, Amarin Switzerland GmbH, Amarin UK Limited, Ester Neurosciences, and Ester Neurosciences Limited.
Read More
This page (NASDAQ:AMRN) was last updated on 3/28/2024 by MarketBeat.com Staff

From Our Partners